Background: Emerging evidence indicates that chemotherapy for lung cancer may alter EGFR mutation status. However, whether chemotherapy as a firstline treatment may increase or reduce the frequency of EGFR mutations in NSCLC remains uncertain. Therefore, we conducted a meta-analysis to evaluate whether chemotherapy leads to altered EGFR mutation status. Methods: A systematic literature search was performed using the PubMed, OVID, Science Direct, Cochrane Library, and CNKI databases for studies on pre-and post-chemotherapy EGFR mutation status. Relevant studies documenting perichemotherapy EGFR mutation ratios were included. Analyses of pooled odds ratios (OR) were performed. Results: Six studies involving 656 patients were included in this meta-analysis. It was found that chemotherapy may alter EGFR status (OR = 1.93, 95% CI 1.05 -3.56; p < 0.0001). No significant differences in EGFR mutation alterations were observed in terms of gender, smoking history, EGFR loci, or chemotherapy response in NSCLC patients. Conclusions: Chemotherapy may contribute to altered EGFR status. NSCLC
Background
Lung cancer causes the majority of cancer deaths in China and worldwide [1] .
Sensitive mutations of the epidermal growth factor receptor (EGFR) have been proven to be highly responsive to EGFR tyrosine kinase inhibitors (EGFR-TKIs) compared to standard chemotherapy [2] [3] in non-small cell lung cancer (NSCLC). However, EGFR-TKIs such as gefitinib or erlotinib are sometimes reserved for second-line or maintenance therapy in clinical practice. The somatic mutation status of the EGFR gene is a crucial biomarker for evaluating the application of EGFR-TKI treatment in patients with metastatic and chemo-resistant NSCLC.
Recent studies have investigated whether EGFR mutations may be altered by chemotherapy. The efficacy of EGFR-TKIs has been shown to be less potent when used as second-line treatment for NSCLC patients refractory to or intolerant of platinum-based combination chemotherapy [4] . On the other hand, some clinical studies have demonstrated increased serum EGFR mutation detection [5] [6] . In 2012, Honda et al. [7] reported a Japanese woman with an initial EGFR mutation (L747-T751 deletion in exon 19 ) that disappeared after chemotherapy. The same year, an oncological study by Bai et al. reported that chemotherapy may reduce the frequency of EGFR mutations in NSCLC patients [8] . Since then, the consideration of altered EGFR mutation status before and after chemotherapy has been tightly linked to the second-line EGFR-TKI treatment of NSCLC, prompting investigations by oncologists into the underlining mechanisms.
The aim of the present study was to systemically combine data from published articles to evaluate the impact of chemotherapy on EGFR mutation status in NSCLC. This meta-analysis is the first attempt to assess the role of chemotherapy in EGFR mutation alterations after standard chemotherapy, using evidencebased methods.
Methods

Literature Search
Relevant studies in English and Chinese were extracted from the PubMed, OVID, Science Direct, Cochrane Library, and China National Knowledge Infra- 119 Open Journal of Genetics structure (CNKI) databases using the following terms: "non-small cell lung cancer", "NSCLC", "carcinoma", "neoplasm", "EGFR mutation", and "chemothera- 
Selection Criteria
Eligible studies were gathered based on the following inclusion criteria: 1) standard chemotherapy as first-line treatment in chemo-naïve or radio-naïve NSCLC patients, 2) EGFR mutation status before and after chemotherapy, 3) any EGFR mutation subtype, 4) standard chemotherapy defined as platinumbased third-generation doublets, and 5) publication in English or Chinese. The exclusion criteria were: 1) duplicate reports, conference abstracts or papers, editorials, or reviews and 2) studies with insufficient data for pooled analysis.
Data Extraction
To identify all eligible research, two investigators (Xiaoshun Shi and Haiyun Mo) independently extracted the data and reached a consensus based on the inclusion criteria. The quality of each study was assessed using the Newcastle Ottawa Quality Assessment Scale. Cases of disagreement were resolved by discussion with a third author. The following information was extracted from the eligible studies: first author's surname, publication year, geographic region, chemotherapy agents used, EGFR detection method, and number of EGFR mutations before and after chemotherapy.
Statistical Analysis
Analysis for the forest plot was conducted using Review Manager 5. Additionally, the trim-and-fill method was used to adjust the risk estimates when the tests for publication bias were statistically significant [20] , which were also analyzed by using STATA version 12.0. P-values of <0.05 were considered statistically significant.
Results
Study Description
A total of 4983 articles were identified in the initial literature search, of which 4970 were rejected based on the exclusion criteria. Two articles were excluded because they belonged to conference abstracts and were subgroups in one of the included articles [8] . Studies with duplicate results, those not documenting EGFR mutation status in the peri-chemotherapy period, and those containing insufficient data for pooled analysis were also excluded. Finally, six articles were identified as eligible for this meta-analysis ( Table 1 ). The total number of patients evaluated before and after chemotherapy was 656. All NSCLC stages were accepted in this meta-analysis. All patients included in the analysis were chemonaïve or radio-naïve prior to the detection of EGFR mutation status. ORs were extracted or calculated from each study ( Figure 1 ). 
Effect of Chemotherapy on EGFR Mutation Status in NSCLC Patients
Six studies were analyzed to examine the impact of chemotherapy on EGFR mutation status. Standard chemotherapy was defined as platinum-based third-generation doublets. The inconsistency index was 81% (p < 0.0001); therefore, a randomeffect model was applied. The result suggested that chemotherapy is a potential risk factor for the alteration of EGFR mutation status in NSCLC patients (OR = 1.93, 95% CI 1.05 -3.56; p < 0.0001) (Figure 2 ).
Impact of Chemotherapy on EGFR Mutations with Regard to Clinicopathological Characteristics
Four studies examined the impact of chemotherapy on EGFR alterations based on gender ( Figure 3 ) and smoking status (Figure 4 ). The impact of chemothe- Figure 2 . Meta-analysis of the effect of chemotherapy on EGFR mutation status in NSCLC patients. 
Impact of Chemotherapy on EGFR Exon Loci
Five studies contained data that could be used to examine the impact of chemotherapy on alterations in the EGFR exon 19 and 21 mutation status [9] [10] [11] [12] [13] . Statistical heterogeneity was found for this outcome. The total pooled OR of altered EGFR status for the exons was 1.83 (95% CI 1.11 -3.03; p = 0.007).
A subgroup analysis showed that in both the EGFR exon 19 (OR = 2.11, 95% CI 0.98 -4.58; p = 0.01) and the exon 21 mutation (OR = 1.60, 95% CI 0.78 -3.27; p = 0.06), chemotherapy was not an independent indicator of altered EGFR mutation status in NSCLC ( Figure 5) . A subgroup analysis of EGFR exon 18 and 20 mutations was not done due to insufficient data.
Chemotherapy Response and EGFR Status
Three studies included the relationship between chemotherapy outcome and EGFR mutation status ( Figure 6 ). 
Effect of Chemotherapy on EGFR Mutation Status Based on Determination Method
The determination of EGFR status in free circulating DNA, as an alternative noninvasive approach to tissue biopsy, has been proposed in recent years. We separated studies with different detection methods for a subgroup analysis and found that the pooled OR value in the invasive-method subgroup was 2.96 (95% CI: 1.01 -8.65) (Figure 7 ). In the non-invasive-method subgroup, the OR value was 1.21 (95% CI: 0.64 -2.27). Therefore, the non-invasive method using blood was unable to detect altered EGFR mutations in our meta-analysis. This suggests that the use of blood for the evaluation of altered EGFR mutation status may not be as sensitive as methods using tissue.
Publication Bias and Sensitivity Analyses
With regard to publication bias, the funnel plots were largely symmetrical, suggesting no significant bias for all outcomes (Figure 8 ).
Discussion
Numerous recent studies have reported that patients with lung cancers harboring EGFR mutations can benefit from EGFR-TKIs, which are now established as first-line treatment options [14] . With the extensive application of EGFR-TKIs, different response rates have been observed between first-line EGFR-TKIs and non-first-line EGFR-TKIs in patients with initial EGFR-positive mutations [5] [15]. In 2012, Honda et al. reported the disappearance of an activated EGFR mutation in a female patient after extensive treatment with cytotoxic drugs [7] .
That same year, Bai et al. [8] proposed that the frequency of EGFR mutations might decrease after chemotherapy. In 2013, Shuhang et al. [13] reported a similar trend. In contrast, Delicia and colleagues [9] reported that the EGFR mutation rate increased from 12.8% to 27.3% after chemotherapy. Honggang and colleagues reported that EGFR mutation status may show an increasing trend [13] . Until now, no study has performed a meta-analysis to illustrate the potential role of chemotherapy in altering EGFR mutation status in NSCLC patients. tained from biopsy, the use of serum ctDNA as guidance for TKI-targeted therapies is still being debated. In this meta-analysis, we analyzed only six studies including both detection methods, suggesting a risk of bias. Second, we could not perform subgroup analyses for different chemotherapy combinations. Irrespective of chemotherapy reagent combinations, the altered EGFR mutation status may vary with platinum-based third-generation doublets, which is worthy of further study. Third, the underlying mechanisms of altered EGFR mutation status could not be identified, as most of the included studies did not mention the biological impact of the EGFR pathway in the peri-chemotherapy period.
Fourth, differences in the quality of the included articles might have led to bias in the meta-analysis. Finally, this meta-analysis only included studies published in the languages of English and Chinese.
Conclusion
Altered EGFR mutation status plays a crucial role in decision-making for EGFR-TKI therapies and subsequent second-line anti-cancer strategies in modern individualized treatment plans. In this meta-analysis, we attempted to include all studies that discussed pre-and post-chemotherapy EGFR status, in or- tissue seems to be superior to blood for determining altered EGFR mutation status. Therefore, it may be necessary to obtain a second EGFR mutation status determination prior to second-line EGFR-TKI therapy and in patients with tumor recurrence following cytotoxic chemotherapy.
